摘要
放疗是治疗恶性肿瘤的重要方法,但对中、晚期恶性肿瘤的疗效仍然较差。因此,寻找新的方法联合治疗以增加放疗效果、降低治疗不良反应势在必行。研究显示,分子靶向药物与放疗联合应用于恶性肿瘤的治疗可增加一些肿瘤细胞的放射敏感性,提高放疗疗效。西妥昔单抗是目前临床上应用最广泛的抗表皮生长因子受体(EGFR)药物之一,也是对联合放疗研究较多的靶向治疗药物之一。笔者拟就西妥昔单抗联合放疗的理论机制及其在恶性肿瘤治疗上的应用,进行综述。
Radiotherapy is the important method to cure malignant tumor, but the curative effect of intermediate stage and advanced stage cancer is still poor. Therefore, a new treatment which can increase the radiation effect and reduce side-effect need to be found. Studies show that the combined application of molecular targeted drugs and radiotherapy can increase the radiosensitivity of some tumor cells and improve the efficacy of radiotherapy. Currently, Cetuximab is one of the most widely used antagonist of epidermal growth factor receptor （EGFR） in clinic, and is also one of the drugs which is discussed more in the research about combined application of molecular targeted drugs and radiotherapy. The theoretical mechanism of cetuximab combined radiotherapy and its application in the treatment of malignant tumor is summarized in this paper.
出处
《中华妇幼临床医学杂志（电子版）》
CAS
2014年第4期128-130,共3页
Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition)
基金
北京市委优秀人才项目(20051D0301028)~~
